Author: admin

Posted on

You wouldn’t think twice about asking your asthma patients to quit smoking, but have you ever asked them whether they have allergic rhinitis?

You wouldn’t think twice about asking your asthma patients to quit smoking, but have you ever asked them whether they have allergic rhinitis?
 
Not such a strange question if you consider that 80% of patients with #asthma have #allergicrhinitis and the presence of uncontrolled rhinitis has the same effect on asthma control as smoking! On the flip side, treating rhinitis effectively improves asthma outcomes. This is because what happens in the nose affects the lungs and vice versa. Therefore, it’s really important to treat both conditions together to optimise outcomes. Don’t forget about rhinitis when reviewing asthma patients! Dr. Toni Hazell, a GP and eLearning Fellow at The Royal College of General Practitioners (RCGP), and Professor David Price from #OPRI discuss more about this in RCGP’s latest #podcast, “Asthma, allergic rhinitis and one airway”.
 
Check out the podcast through this link: https://lnkd.in/drHQZ3_5
Apple Podcast: https://lnkd.in/dFkQNs6G
Google Podcast: https://lnkd.in/dV67qyxA
Spotify: https://lnkd.in/dXr8yWeQ

Posted on

OPRI is excited to share a milestone in asthma phenotype recognition! 

OPRI is excited to share a milestone in asthma phenotype recognition! 

The ISAR #publication titled, ”Eosinophilic and Non eosinophilic Asthma, An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort” found that >80% patients in severe asthma centres have eosinophilic asthma which is more than previously thought. The eosinophilic phenotype was identified using #ISAR’s Gradient Eosinophilic Phenotype Algorithm, an evidence-based and consensus-driven algorithm using readily available variables in real life. The value of this algorithm, is that physicians can now easily recognize the type of asthma their patients have, identify treatable traits and confidently prescribe phenotype-directed treatments.
 
With nearly 7000 downloads as of 31 December 2021, it was the TOP downloaded paper on chestjournal.org and ScienceDirect in 2021!

Check out the full article: https://lnkd.in/eWfjXkD

Slide set that offers a quick overview of the article: https://lnkd.in/gkyj7Aw5

Posted on

Are severe asthma patients getting the right treatment?

Are severe asthma patients getting the right treatment?

Research has shown that you can’t take a one-size-fits-all approach to severe asthma management due to differences in phenotypes. So, we developed the International Severe Asthma Registry (ISAR) Eosinophil Phenotype Gradient Algorithm to quantify the eosinophilic phenotype in severe asthma. Using this algorithm, we found 50.3% of patients in UK primary care to be eosinophilic, 22.2% were likely eosinophilic, 21.9% were unlikely eosinophilic and just 5.6% to be non-eosinophilic. What’s more, eosinophilic patients had more exacerbations and greater healthcare resource utilization. In the age of personalized medicine, eosinophilic phenotyping will allow asthma patients to be identified and categorized with and without eosinophilic asthma in primary care and to be referred for phenotype-targeted treatment.

Check out the summary of our research published on the American Academy of Allergy, Asthma & Immunology website: https://lnkd.in/g_mqzdKE, and our full manuscript: https://lnkd.in/g4ensymQ


#ISAR #eosinophil #personalisedmedicine #healthcare #severeasthma

Posted on

ISAR@REG Feb’22 newsletter

The February issue of REG’s newsletter is out – and ISAR has been featured in it!

This ISAR report contains exciting details on the ISAR Open Research Meeting and ISAR Steering Committee Meeting (17th March 2022), as well as the ISAR Sessions at the REG Summit 2022 (19th March 2022). Read about the Spectator Briefings podcast featuring ISAR, in addition to our usual operational, publications, and research updates here: https://lnkd.in/gYGYdpvG

You may find the full REG newsletter for February 2022 and all previous issues at this link: https://lnkd.in/eGu_RkdE
Link to ISAR Newsletter March 2022: https://lnkd.in/gwjCguPx
Link to all ISAR Newsletters: https://lnkd.in/gMdpdynF

#severeasthma #asthma #resipratory #research #registry #ISAR

Posted on

Dissemination of ISAR SUNNIE

Biologics for severe asthma: time to switch it up?

Ever wondered about the pattern of use of biologics in real-life? Or whether the first biologic prescribed to a patient is the best one for that individual? This study explored these questions and more, using data from both ISAR and CHRONICLE and found, quite surprisingly, that even in a world with multiple biologic choices for severe asthma only about 11% of patients switched from one biologic to another and even a smaller proportion (10%) stopped. Interestingly if a change to biologic therapy was made, the pattern of switch vs ditch was country dependent. Some countries like the US, UK and Spain leaned towards stopping, while others like Kuwait, Bulgaria, Canada, Denmark, South Korea, Italy and Greece were more likely to switch. So, are we getting it right from the get-go, or are we under-switching?

Check out this figure to see the most common biologic switch patterns. 

Link to full article: https://lnkd.in/g2KRYG6E
Link to summary slide set: https://lnkd.in/g7ENk4sr
You can also see a summary of ISAR research: https://lnkd.in/g7ENk4sr

#severe asthma #ISAR #biologics #healthcare

Pattern of biologic switch (n=377)
No alternative text description for this image
Posted on

Dissemination of ISAR BACS

Precision or country and post-code medicine? 

This study showed a high degree of variability in ease of access to severe asthma biologics across countries. In fact, the vast majority of countries surveyed had more stringent access criteria than those stipulated by EMA! Our newly developed biologic accessibility score (BACS) allows you to see at a glance how easy or difficult it is to access biologics in your country. Check out this figure to see how you compare to other countries for access to benralizumab. 

For more details, you can access the full article here: https://lnkd.in/gZBJPiqE
Download a summary slide set: https://lnkd.in/gTFUTqky
Link to ISAR research summary slide set: https://lnkd.in/gC9j2phA

#ISAR #Severeasthma #Biologicaccessibility #Biologiceligibility #personalisedmedicine

Biologic accessibility scores for benralizumab around the world.
No alternative text description for this image
Posted on

MHP – AstraZeneca UK/Spectator podcast

We are delighted to share a new #podcast, “Improving the status quo – can severe asthma be better treated?” on @The Spectator Briefings!

We chat about the experiences of Gabby Perry, a student with severe #asthma, and the dual-edged swords that are steroids. Along with Gabby, Syed Ali, medical affairs manager at AstraZeneca, and OPRI’s own Professor David Price take us through the patient experience in consuming steroids, the cost of prescribing steroids for NHS, alternative treatments such as biologics, and the role of #ISAR in understanding #severeasthma.

This podcast was sponsored by @AstraZeneca.

Check out the podcast through this link: https://lnkd.in/gPWVKCtT. (Also available on podcast distribution services such as Player FM.)

#podcast #severeasthma #ISAR

Posted on

International Severe Asthma Registry (ISAR) Newsletter (December 2021 issue)

International Severe Asthma Registry (ISAR) Newsletter.

We are delighted to share the December 2021 issue of the ISAR biannual newsletter! Read about our continued growth in patient recruitment numbers, research and publication updates, e-Posters presented at the ERS congress 2021, quality improvement initiatives, and past and upcoming events.

Link to ISAR website:  www.isaregistries.org
Link to ISAR newsletter: https://lnkd.in/eKZbadKn
Link to ISAR research summary slide set: https://lnkd.in/g4Dvc5m

#severe asthma #healthcare #research #publications #quality improvement #ISAR #newsletter

Posted on

3 abstracts using data from the International Severe Asthma Registry (ISAR) are now published in a supplement of the European Respiratory Journal

We are delighted to announce that 3 abstracts using data from the International Severe Asthma Registry (ISAR) are now published in a supplement of the European Respiratory Journal!
 
Link to Journal: https://lnkd.in/eS_ePv5M
Link to ISAR webpage: https://lnkd.in/eVHzgC6M
 
ERS 2021 abstracts:
1. Baseline characteristics of severe asthma patients initiating biologic treatment worldwide (BEAM):
Link: https://lnkd.in/egB37Hsz 
 
2. Comparative effectiveness of anti-IL5/5R versus anti-IgE in patients eligible for both (FIRE): 
Link: https://lnkd.in/evj9VWkv
 
3. Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not (GLITTER): 
Link: https://lnkd.in/eWAYbdDM
 
Description of ISAR:
ISAR is the first global adult severe asthma registry that stores standardized severe asthma data which can be shared for clinical and research purposes. The Delphi method was used to identify a standardized set of core variables to be collected by registries contributing to ISAR. ISAR currently has 25 collaborating countries in the Americas, Asia, Australasia, Europe and the Middle East. ISAR’s research is governed by the Respiratory Effectiveness Group via the Anonymised Data Ethics and Protocol Transparency (ADEPT) committee and is overseen by the ISAR steering committee (ISC) consisting of global severe asthma experts.
 
Link to ISAR: www.isaregistries.org
 
#research #healthcare #database #asthma #biologics #ISAR

Posted on

Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-based Cohort Study from UK Primary Care.

Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-based Cohort Study from UK Primary Care.

In this study, we investigated the effects of socioeconomic status (SES) on clinical outcomes in a UK primary care asthma cohort (N=127,040) from the Optimum Patient Care Research Database (OPCRD). There was evidence of socioeconomic disparities, which had adverse effects on asthma outcomes.

Patients from the most deprived quintile were more likely to have decreased peak flow, uncontrolled asthma or an exacerbation during follow-up than those from the least deprived quintile, yet their rates of respiratory referrals remained comparable. This should raise clinical awareness that more deprived patients may have greater need for specialist reviews and phenotype-targeted treatments like biologics. This study also demonstrated that the magnitude of the impact of SES on asthma outcomes was greater in patients who were older or from ethnic minority groups. Interventions to resolve socioeconomic disparities should be explored, both in the UK and globally, to improve overall asthma outcomes.

Link to article: https://lnkd.in/eiyWtgXX
Link to slide set: https://lnkd.in/g4Dvc5m
Link to ISAR research summary slide set: https://lnkd.in/g4Dvc5m
Link to ISAR: www.isaregistries.org
Link to OPCRD: www.opcrd.co.uk

#healthcare #primarycare #OPCRD #socioeconomic #asthma